Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice

Journal of Immunology

Volumn 170, Issue 1, 2003, Pages 308-314

  Voice, Julia K ^a   Grinninger, Carola ^a   Kong, Yvonne ^a   Bangale, Yogesh ^b   Paul, Sudhir ^b   Goetzl, Edward J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; RECEPTOR SUBTYPE; T LYMPHOCYTE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EOSINOPHIL; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; WILD TYPE;

EID: 0037218515     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.1.308     Document Type: Article

References (32)

1. Said, S. I., and V. Mutt. 1988. Vasointestinal peptide and related peptides. Ann. NY Acad. Sci. 527:1.
2. Gomariz, R. P., J. Leceta, E. Garrido, T. Garrido, and M. Delgado. 1994. Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul. Pept. 50:177.
3. Bellinger, D. L., D. Lorton, S. Brouxhon, S. Felten, and D. L. Felten. 1996. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6:5.
4. Dorsam, G., J. Voice, Y. Kong, and E. J. Goetzl. 2000. Vasoactive intestinal peptide mediation of development and functions of T lymphocytes. Ann. NY Acad Sci. 921:79.
5. Goetzl, E. J., and S. P. Sreedharan. 1992. Mediators of communication and adaptation in the neuroendocrine and immune systems. FASEB J. 6:2646.
6. Ganea, D. 1996. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:61.
7. Johnston, J. A., D. D. Taub, A. R. Lloyd, K. Conlon, J. J. Oppenheim, and D. J. Kevlin. 1994. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. J. Immunol. 153:1762.
8. Martinez, C., M. Delgado, R. P. Gomariz, and D. Ganea. 1996. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156:4128.
9. Xia, M., D. Leppert, S. L. Hauser, S. P. Sreedharan, P. J. Nelson, A. M. Krensky, and E. J. Goetzl. 1996. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J. Immunol. 156:160.
10. Hemanz, A., E. Tato, M. De la Fuente, E. de Miguel, and F. Arnalich. 1996. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-α production by whole blood cells from healthy young and old subjects. J. Neuroimmunol. 71:25.
11. Pankhaniya, R., N. Jabrane Ferrat, G. O. Gaufo, S. P. Sreedharan, P. Dazin, J. Kaye, and E. J. Goetzl, 1998. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J. 12:119.
12. Mathew, R. C., G. A. Cook, A. M. Blum, A. Metwali, R. Felman, and J. V. Weinstock. 1992. Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection. J. Immunol. 148:3572.
13. Sun, L., and D. Ganea. 1993. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J. Neuroimmunol. 48:59.
14. Wang, H. Y., Z. Xin, H. Tang, and D. Ganea. 1996. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156:3243.
15. Jabrane-Ferrat, N., D. Bloom, A. Wu, L. Li, D. Lo, S. P. Sreedharan, C. W. Turck, and A. E. Goetzl. 1999. Enhancement by vasoactive intestinal peptide of γ-interferon production by antigen-stimulated type 1 helper T cells. FASEB J. 13:347.
16. Sreedharan, S. P., J. X. Huang, M. C. Cheung, and E. J. Goetzl. 1995. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc. Natl. Acad. Sci. USA 92:2939.
17. Mackay, M., J. Fantes, S. Scherer, S. Boyle, K. West, L. C. Tsui, E. Belloni, E. Lutz, V. Van Heyningen, and A. J. Harmar. 1996. Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: A possible contributor to the holoprosencephaly 3 phenotype. Genomics 37:345.
18. Delgado, M., C. Martinez, M. C. Johnson, R. P. Gomariz, and D. Ganea. 1996. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68:27.
19. Harmar, A. J., A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al. 1998. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50:265.
20. Kaltreider, H. B., S. Ichikawa, P. K. Byrd, D. A. Ingram, J. L. Kishiyama, S. P. Sreedharan, M. L. Warnock, J. M. Beck, and E. J. Goetzl. 1997. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am. J. Respir. Cell Mol. Biol. 16:133.
21. Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G. J. Shei, D. Card, C. Keohane, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346.
22. Delgado, M., and D. Ganea. 2001. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166:2907.
23. Lara-Marquez, M., M. O'Dorisio, T. O'Dorisio, M. Shah, and B. Karacay. 2001. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Iq 25mmunol. 166:2522.
24. Voice, J. K., G. Dorsam, H. Lee, Y. Kong, and E. J. Goetzl. 2001. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15:2489.
25. 2 receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA 98:13854.
26. Xia, M., S. P. Sreedharan, D. R. Bolin, G. O. Gaufo, and E. J. Goetzl. 1997. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:629.
27. Gourlet, P., A. Vandermeers, P. Vertongen, J. Rathe, P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht. 1997. Development of high affinity selective VIP1 receptor agonists. Peptides 18:1539.
28. Paul, S., M. Sun, R. Mody, H. K. Tewary, P. Stemmer, R. J. Massey, T. Gianferrara, S. Mehrotra, T. Dreyer, M. Meldal, et al. 1992. Peptidolytic monoclonal antibody elicited by a neuropeptide. J. Biol. Chem. 267:13142.
29. Goetzl, E. J., K. T. Kodama, C. W. Turck, S. A. Schiogolev, and S. P. Sreedharan. 1989. Unique pattern of cleavage of vasoactive intestinal peptide by human lymphocytes. Immunology 66:554.
30. Sun, M., Q. S. Gao, L. Kimarskiy, A. Rees, and S. Paul. 1997. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J. Mol. Biol. 271:374.
31. Delgado, M., J. Leceta, W. Sun, R. P. Gomariz, and D. Ganea. 2000. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann. NY Acad. Sci. 921:68.
32. Delgado, M., and D. Ganea. 2001. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-κB, NF-AT, and early growth factors 2/3. J. Immunol. 166:1028.